

RECEIVED

MAY 22 2003

PATENT

☐ PROVISIONAL
☒ UTILITY

Application No.: 09/933,708
Client/Matter No.: 54719.000028
Inventor(s): Piccariello et al.

☐ DESIGN
☐ PCT
Date: March 26, 2003
Client: New River Pharmaceuticals
Atty/Sec.: JP/jt

TECH CENTER 1600/2900

Title: ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR
PROTECTING AND ADMINISTERING ACTIVE AGENTS

The following has been received in the U.S. Patent and Trademark
Office on the date stamped hereon:

☒ Information Disclosure Statement
☒ SB/08A forms (5 pages)
☒ All documents listed on SB/08A forms
43





RECEIVED

APR 15 2003
TECH CENTER 1600/2900

DOCKETED

ram
3-27-03





Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	09/933,708
Filing Date	August 22, 2001
First Named Inventor	Thomas PICCARIELLO et al.
Group Art Unit	1653
Examiner Name	Unassigned
Attorney Docket Number	54719.000028

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P49	CANARIS, G., "The Colorado Thyroid Disease Prevalence Study," Archives Internal Medicine Articles and Abstracts, Vol. 160, No. 4 (2000).	
	P50	BUNEVICIUS, R., "Effects of Thyroxine as Compared with Thyroxine Plus Triiodothyronine in Patients with Hypothyroidism," <i>The New England Journal of Medicine</i> , Vol. 340, No. 6 (1999).	
	P51	TOFT, A., "Thyroid Hormone Replacement -- One Hormone or Two?," <i>The New England Journal of Medicine</i> , Vol. 340, No. 6 (1999).	
	P52	PADE, V., et al., "Link Between Drug Absorption Solubility and Permeability Measurements in Caco-2 Cells," <i>Journal of Pharmaceutical Sciences</i> , Vol. 87, No. 12 (1998).	
	P53	OH, D., et al., "Estimating the Fraction Dose Absorbed from Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model," <i>Pharmaceutical Research</i> , Vol. 10, No. 2 (1993).	
	P54	AMIDON, G., et al., "A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of <i>in Vitro</i> Drug Product Dissolution and <i>in Vivo</i> Bioavailability," <i>Pharmaceutical Research</i> , Vol. 12, No. 3 (1995).	
	P55	Presentation to Knoll Pharmaceutical, April 10, 2000.	
	P56	Investment Banking Presentation, March 27-31, 2000	
	P57	Pharma Presentation, March 27-31, 2000, New York, NY.	
	P58	Deutsche Banc Alex Brown 2000 Health Care Conference Presentation, May 10, 2000, Baltimore, MD.	
	P59	April 7, 2000, Letter to Credit Suisse First Boston Corporation	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	09/933,708
Filing Date	August 22, 2001
First Named Inventor	Thomas PICCARIELLO et al.
Group Art Unit	1653
Examiner Name	Unassigned
Attorney Docket Number	54719.000028

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P60	April 7, 2000, Letter to Chase, Hambrecht and Quist	
	P61	April 7, 2000, Letter to Banc of America Securities, LLC	
	P62	April 7, 2000, Letter to Johnson & Johnson	
	P63	April 7, 2000, Letter to AstraZeneca LP	
	P64	April 7, 2000, Letters to Bear, Stearns & Company, Inc.	
	P65	Bankers Presentation, March 27-31, 2000	
	P66	Pharmaceutical Presentation, March 27-31, 2000	
	P67	KPMG Auditors' Report, March 12, 1999	
	P68	Final Report, Study Completion Date June 25, 1998	
	P69	Investment Banking Presentation, March 27-31, 2000	
	P70	Pharmaceutical Presentation, March 27-31, 2000	


Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/933,708		
		Filing Date	August 22, 2001		
		First Named Inventor	Thomas PICCARIELLO et al.		
		Group Art Unit	1653		
		Examiner Name	Unassigned		
Sheet	4	of	5	Attorney Docket Number	54719.000028

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P71	Deutsche Banc Alex Brown 2000 Health Care Conference Presentation, May 10, 2000, Baltimore, MD.	
	P72	Investment Banking (short) Presentation, April 27, 2000	
	P73	Investment Banking (long) Presentation, April 27, 2000	
	P74	Banc of America Presentation	
	P75	Pharma Presentation, April 2000	
	P76	AstraZeneca Presentation	
	P77	"Promise of Polythroid," Presentation, March 2000	
	P78	"Introducing Polythroid," Presentation, March 2000	
	P79	Investment Banking Presentation	
	P80	Pharma Presentation, March-April	
	P81	Deutsche Banc Alex Brown 2000	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	09/933,708
Filing Date	August 22, 2001
First Named Inventor	Thomas PICCARIELLO et al.
Group Art Unit	1653
Examiner Name	Unassigned
Attorney Docket Number	54719.000028

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P82	August 31, 1999 Presentation to Scios, Inc.	
	P83	February 2000 Presentation to Andrx	
	P84	March 15, 2000 Presentation to BASF	
	P85	Original Presentation to BASF	
	P86	February 10, 2000 Lotus Presentation	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.